Extrawell Pharmaceutical Holdings Limited (0858.HK)
HKD 0.05
(2.04%)
HKD 0.05
(2.04%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -162.94 Million HKD | -226.06% |
| 2022 | 129.26 Million HKD | -1.01% |
| 2021 | 130.58 Million HKD | 207.84% |
| 2020 | -121.09 Million HKD | -245.41% |
| 2019 | 83.28 Million HKD | 30.06% |
| 2018 | 64.03 Million HKD | 113.93% |
| 2017 | 29.93 Million HKD | 43.92% |
| 2016 | 20.79 Million HKD | -24.1% |
| 2015 | 27.4 Million HKD | -95.15% |
| 2014 | 565.45 Million HKD | 3501.64% |
| 2013 | 15.7 Million HKD | 44.35% |
| 2012 | 10.87 Million HKD | -46.72% |
| 2011 | 20.41 Million HKD | 76.48% |
| 2010 | 11.56 Million HKD | -20.9% |
| 2009 | 14.62 Million HKD | -5.96% |
| 2008 | 15.55 Million HKD | 216.62% |
| 2007 | -13.33 Million HKD | -249.26% |
| 2006 | 8.93 Million HKD | 113.37% |
| 2005 | 4.18 Million HKD | 105.52% |
| 2004 | -75.82 Million HKD | -617.88% |
| 2003 | 14.64 Million HKD | -68.64% |
| 2002 | 46.68 Million HKD | 11.16% |
| 2001 | 42 Million HKD | 104.49% |
| 2000 | 20.54 Million HKD | 46.27% |
| 1999 | 14.04 Million HKD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 FY | -162.94 Million HKD | -226.06% |
| 2023 Q2 | -237.72 Million HKD | 0.0% |
| 2023 Q4 | 74.77 Million HKD | 0.0% |
| 2022 Q4 | 83.44 Million HKD | 0.0% |
| 2022 FY | 129.26 Million HKD | -1.01% |
| 2022 Q2 | 45.82 Million HKD | 0.0% |
| 2021 FY | 130.58 Million HKD | 207.84% |
| 2021 Q2 | 88.59 Million HKD | 0.0% |
| 2021 Q4 | 41.99 Million HKD | 0.0% |
| 2020 Q4 | -196.09 Million HKD | 0.0% |
| 2020 FY | -121.09 Million HKD | -245.41% |
| 2020 Q2 | 74.99 Million HKD | 0.0% |
| 2019 FY | 83.28 Million HKD | 30.06% |
| 2019 Q2 | 25.04 Million HKD | 0.0% |
| 2019 Q4 | 58.23 Million HKD | 0.0% |
| 2018 FY | 64.03 Million HKD | 113.93% |
| 2018 Q4 | 37.62 Million HKD | 0.0% |
| 2018 Q2 | 26.4 Million HKD | 0.0% |
| 2017 Q2 | 17.72 Million HKD | 0.0% |
| 2017 Q4 | 12.2 Million HKD | 0.0% |
| 2017 FY | 29.93 Million HKD | 43.92% |
| 2016 Q4 | 16.07 Million HKD | 0.0% |
| 2016 FY | 20.79 Million HKD | -24.1% |
| 2016 Q2 | 4.72 Million HKD | 0.0% |
| 2015 Q1 | 141.36 Million HKD | 0.0% |
| 2015 Q4 | 66.37 Million HKD | 0.0% |
| 2015 Q2 | -33.59 Million HKD | -123.76% |
| 2015 FY | 27.4 Million HKD | -95.15% |
| 2014 Q2 | 3.15 Million HKD | -19.59% |
| 2014 Q1 | 3.92 Million HKD | 0.0% |
| 2014 Q3 | 141.36 Million HKD | 4379.22% |
| 2014 Q4 | 141.36 Million HKD | 0.0% |
| 2014 FY | 565.45 Million HKD | 3501.64% |
| 2013 FY | 15.7 Million HKD | 44.35% |
| 2013 Q4 | 3.92 Million HKD | 0.0% |
| 2013 Q3 | 3.92 Million HKD | -17.75% |
| 2013 Q2 | 4.77 Million HKD | 75.51% |
| 2013 Q1 | 2.71 Million HKD | -30.08% |
| 2012 Q2 | 5.1 Million HKD | 0.0% |
| 2012 Q1 | 5.1 Million HKD | 0.0% |
| 2012 Q4 | 3.88 Million HKD | 43.03% |
| 2012 FY | 10.87 Million HKD | -46.72% |
| 2012 Q3 | 2.71 Million HKD | -46.72% |
| 2011 FY | 20.41 Million HKD | 76.48% |
| 2011 Q1 | 2.89 Million HKD | 0.0% |
| 2011 Q2 | 2.89 Million HKD | 0.0% |
| 2011 Q3 | 5.1 Million HKD | 76.48% |
| 2011 Q4 | 5.1 Million HKD | 0.0% |
| 2010 FY | 11.56 Million HKD | -20.9% |
| 2010 Q1 | 3.65 Million HKD | 0.0% |
| 2010 Q4 | 2.89 Million HKD | 0.0% |
| 2010 Q3 | 2.89 Million HKD | -20.9% |
| 2010 Q2 | 3.65 Million HKD | 0.0% |
| 2009 Q3 | 3.65 Million HKD | -5.96% |
| 2009 Q4 | 3.65 Million HKD | 0.0% |
| 2009 FY | 14.62 Million HKD | -5.96% |
| 2009 Q1 | 3.88 Million HKD | 0.0% |
| 2009 Q2 | 3.88 Million HKD | 0.0% |
| 2008 FY | 15.55 Million HKD | 216.62% |
| 2008 Q1 | -3.33 Million HKD | 0.0% |
| 2008 Q4 | 3.88 Million HKD | 0.0% |
| 2008 Q2 | -3.33 Million HKD | 0.0% |
| 2008 Q3 | 3.88 Million HKD | 216.62% |
| 2007 Q1 | 2.23 Million HKD | 0.0% |
| 2007 FY | -13.33 Million HKD | -249.26% |
| 2007 Q4 | -3.33 Million HKD | 0.0% |
| 2007 Q3 | -3.33 Million HKD | -249.26% |
| 2007 Q2 | 2.23 Million HKD | 0.0% |
| 2006 Q4 | 2.23 Million HKD | 0.0% |
| 2006 FY | 8.93 Million HKD | 113.37% |
| 2006 Q2 | 1.04 Million HKD | 0.0% |
| 2006 Q3 | 2.23 Million HKD | 113.37% |
| 2006 Q1 | 1.04 Million HKD | 0.0% |
| 2005 Q1 | -18.95 Million HKD | 0.0% |
| 2005 Q2 | -18.95 Million HKD | 0.0% |
| 2005 FY | 4.18 Million HKD | 105.52% |
| 2005 Q3 | 1.04 Million HKD | 105.52% |
| 2005 Q4 | 1.04 Million HKD | 0.0% |
| 2004 Q4 | -18.95 Million HKD | 0.0% |
| 2004 Q1 | 3.66 Million HKD | 0.0% |
| 2004 Q2 | 3.66 Million HKD | 0.0% |
| 2004 Q3 | -18.95 Million HKD | -617.88% |
| 2004 FY | -75.82 Million HKD | -617.88% |
| 2003 Q1 | 11.67 Million HKD | 0.0% |
| 2003 FY | 14.64 Million HKD | -68.64% |
| 2003 Q4 | 3.66 Million HKD | 0.0% |
| 2003 Q3 | 3.66 Million HKD | -68.64% |
| 2003 Q2 | 11.67 Million HKD | 0.0% |
| 2002 FY | 46.68 Million HKD | 11.16% |
| 2002 Q4 | 11.67 Million HKD | 0.0% |
| 2002 Q3 | 11.67 Million HKD | 11.16% |
| 2002 Q2 | 10.5 Million HKD | 0.0% |
| 2002 Q1 | 10.5 Million HKD | 0.0% |
| 2001 FY | 42 Million HKD | 104.49% |
| 2001 Q4 | 10.5 Million HKD | 0.0% |
| 2001 Q3 | 10.5 Million HKD | 104.49% |
| 2001 Q2 | 5.13 Million HKD | 0.0% |
| 2001 Q1 | 5.13 Million HKD | 0.0% |
| 2000 Q4 | 5.13 Million HKD | 0.0% |
| 2000 Q3 | 5.13 Million HKD | 46.27% |
| 2000 Q2 | 3.51 Million HKD | 0.0% |
| 2000 Q1 | 3.51 Million HKD | 0.0% |
| 2000 FY | 20.54 Million HKD | 46.27% |
| 1999 Q3 | 3.51 Million HKD | 0.0% |
| 1999 Q4 | 3.51 Million HKD | 0.0% |
| 1999 FY | 14.04 Million HKD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | 255.132% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 108.668% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | -961.142% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | -209.172% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | 1075.859% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 159.198% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | -464.952% |
| PuraPharm Corporation Limited | -106.08 Million HKD | -53.608% |
| SSY Group Limited | 1.31 Billion HKD | 112.358% |
| JBM (Healthcare) Limited | 130.46 Million HKD | 224.901% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 161.037% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 104.228% |